Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

According to the CDC, more than 38 million Americans have diabetes. This warning is for people who use diabetes apps like continuous glucose monitors, insulin pumps, and other diabetes management ...

Advanced sensing features are coming to wearables beginning in 2025 and Penn State’s device, made with laser-modified ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. "With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality." The prospective single ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...